Century Therapeutics Inc
IPSC
NASDAQ
Biotechnology
$1.92
USD
-0.01 (-0.52%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $348.08M
Volume 489.3K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-109.79M
TTM
-371.7%
YoY
Operating Cash Flow
$-86.76M
TTM
+24.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | -100.0% | -100.0% | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 7.8 | 6.8 | 1.0 | 6.6 | 5.8 |
Other Operating Expenses | 0.0 | 6.8 | 0.0 | 0.0 | 11.1 |
Total Operating Expenses | 34.7 | 36.1 | 20.7 | 23.7 | 36.5 |
Operating Income | -34.7 | -36.1 | -20.7 | -23.7 | -36.5 |
EBITDA | -31.5 | -26.2 | -17.1 | -20.7 | -22.8 |
Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.0 | -0.0 |
Total Other Income / Expense | 2.1 | 1.7 | 1.4 | 2.0 | 2.0 |
Income Before Income Taxes | -32.5 | -34.4 | -19.2 | -21.6 | -34.6 |
Income Taxes | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 |
Net Income | -32.5 | -34.4 | -19.2 | -21.6 | -34.6 |
Consolidated Net Income / Loss | -32.5 | -34.4 | -19.2 | -21.6 | -34.6 |
Net Income Attributable to Common Shareholders | -32.5 | -34.4 | -19.2 | -21.6 | -34.6 |
Basic EPS | -$0.38 | -$0.40 | -$0.22 | -$0.11 | -$0.17 |
Diluted EPS | -$0.38 | -$0.40 | -$0.22 | -$0.11 | -$0.17 |
Basic Shares Outstanding | 86.2M | 86.5M | 87.5M | 193.5M | 205.8M |
Diluted Shares Outstanding | 86.2M | 86.5M | 87.4M | 193.5M | 205.8M |